Hubertus von Baumbach’s net worth over time
Only dates with a published estimate are shown. Nothing is filled in between. Tap or hover a bar to see the source.
See the numbers as a table
| Date | Estimate | Source |
| 2025 | $5.4 billion | Forbes World's Billionaires List 2025 |
| 2026 | $6.6 billion | Forbes World's Billionaires List 2026 |
| Oct 2026 | $6.3 billion | Forbes Real-Time Billionaires · Forbes real-time estimate |
Where the money comes from
These are the main sources of wealth named in the reporting we cite. No published source breaks the total into exact amounts, so we do not show percentages.
Hubertus von Baumbach’s fortune in real-life terms
Based on the Forbes Real-Time Billionaires estimate above. Median full-time U.S. pay is $65,416 a year ($1,258 a week, BLS, Q2 2026), before taxes. Typical (median) U.S. family net worth is $216,100 (Federal Reserve, 2025 Survey of Consumer Finances).
How do you compare to Hubertus von Baumbach? New
Type your yearly income and see how you stack up. It runs in your browser: nothing you type is saved or sent anywhere.
Hubertus von Baumbach has an estimated net worth of $6.3 billion, according to Forbes Real-Time Billionaires, Hubertus von Baumbach profile (figures as of October 20, 2026). That is up from $5.4 billion in 2025.
Hubertus von Baumbach is a German businessman who leads Boehringer Ingelheim as chairman and CEO. He is an heir to the company founded in 1885 by Albert Boehringer. The business started by supplying ingredients to pharmacies, textile merchants and the food industry. It opened a research department in 1917 with chemist Heinrich Wieland and had a workforce of 1,500 by 1939. Today it is the world's largest private pharmaceutical company and Germany's second largest pharmaceutical company.
He joined Boehringer Ingelheim in 2001 and later served as CFO. In November 2015, the company said he would become chief executive in June 2016, succeeding Andreas Barner. That made him the first family member to lead the company in 25 years. In his first six months, he launched the biggest acquisition in the company's history through an asset swap deal with Sanofi. He then reorganized the group into a more decentralized divisional structure.
How Hubertus von Baumbach makes money
Von Baumbach's wealth comes from his family's stake in Boehringer Ingelheim, a pharmaceutical company based in Germany. Forbes places him in healthcare and ties his fortune to pharma. He owns the company alongside 14 members of the family, with equal parts. The business has deep roots, but its modern size matters most to his fortune. Boehringer Ingelheim now has 53,000 employees and operates in 130 markets.
The company is known for medicines used to treat COPD, anti-coagulation and type 2 diabetes. Those products sit at the center of the family's wealth. Von Baumbach joined the company in 2001 and became chairman in 2016. Soon after taking over as chief executive, he oversaw an asset swap with Sanofi, described as the biggest acquisition in the company's history, and followed that with a reorganization that gave the group a more decentralized divisional structure.
Forbes net worth timeline
Forbes estimated Hubertus von Baumbach's fortune at $5.4 billion on the World's Billionaires List in 2025. On the 2026 list, Forbes put it at $6.6 billion. Those estimates follow the value Forbes assigns to his ownership in Boehringer Ingelheim, the private drugmaker his family controls. Because the company is private, changes in the estimate reflect Forbes' view of the business and the family's holdings.
As of October 20, 2026, Forbes' real-time billionaires tracker showed his net worth at $6.3 billion. That was below the 2026 annual list estimate, but it still pointed to the scale of his position in one of Germany's biggest drugmakers. The company remains central to his wealth: it is headquartered in Germany, reaches 130 markets, employs 53,000 people, and is still owned in equal parts by him and 14 relatives.
Career and money timeline
- 1885
Albert Boehringer founded Boehringer Ingelheim.
- 1917
The company opened a research department with Heinrich Wieland.
- 1939
Boehringer Ingelheim had grown to a workforce of 1,500.
- 2001
Hubertus von Baumbach joined Boehringer Ingelheim.
- 2015
In November, the company announced he would become chief executive.
- 2016
He became chairman and chief executive and led a major Sanofi asset swap.
Hubertus von Baumbach net worth FAQ
What is Hubertus von Baumbach's net worth?
Hubertus von Baumbach's net worth is an estimated $6.3 billion, according to Forbes Real-Time Billionaires, Hubertus von Baumbach profile (October 20, 2026). It is an estimate, not an official figure.
How did Hubertus von Baumbach get so rich?
The main sources named in the reporting we cite are: Pharma.
Is Hubertus von Baumbach a billionaire?
Yes. Forbes Real-Time Billionaires estimates Hubertus von Baumbach is worth $6.3 billion.
How has Hubertus von Baumbach's net worth changed?
The earliest published estimate we track is $5.4 billion (2025, Forbes World's Billionaires List 2025). The latest is $6.3 billion (October 20, 2026).
What company is Hubertus von Baumbach known for?
He is known for leading Boehringer Ingelheim as chairman and CEO. The company is the world's largest private pharmaceutical company.
How does Hubertus von Baumbach make his money?
His wealth comes from his family's ownership of Boehringer Ingelheim. He owns equal parts of the company alongside 14 relatives.
Sources
- Forbes Real-Time Billionaires, Hubertus von Baumbach profile (October 20, 2026)
- Forbes World's Billionaires List 2025, Hubertus von Baumbach profile (April 2025)
- Forbes World's Billionaires List 2026, Hubertus von Baumbach profile (March 10, 2026)
- U.S. Bureau of Labor Statistics, Usual Weekly Earnings (Q2 2026) (July 2026)
- Federal Reserve, 2025 Survey of Consumer Finances (median family net worth, Table 4) (October 2026)
- Background facts: Wikipedia, Hubertus von Baumbach (accessed October 22, 2026). Used for career facts only, never for figures.
Every number on this page is an estimate published by the source named next to it. We never fill in years with our own guesses. How we handle estimates.